Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 28Terminated 7Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Cyclophosphamide 37Etoposide 25Vincristine 24Cytarabine 21Doxorubicin 19Rituximab 17Radiotherapy 17Peripheral Blood Stem Cell Transplantation 16Melphalan 16Prednisolone 14Methotrexate 14Filgrastim 13fludarabine phosphate 11Prednisone 11Dexamethasone 11Carmustine 9Bleomycin 9pegylated granulocyte colony-stimulating factor 8Cyclosporine 8Busulfan 8fludarabine 7Ifosfamide 7Cisplatin 7sargramostim 6Vinblastine 6Mitoxantrone 6Methylprednisolone 6Gemcitabine 6Chlorambucil 6Antilymphocyte Serum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma × ibritumomab tiuxetan × Clear all
NCT00397800 2012-08-28

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Technical University of Munich

Phase 1/2 Unknown
12 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡